# A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

> **NCT02460068** · PHASE3 · UNKNOWN · sponsor: **Italian Network for Tumor Biotherapy Foundation** · enrollment: 168 (estimated)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** Fotemustine
- **DRUG:** Fotemustine and Ipilimumab
- **DRUG:** Ipilimumab and nivolumab

## Key facts

- **NCT ID:** NCT02460068
- **Lead sponsor:** Italian Network for Tumor Biotherapy Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2018-01
- **Final completion:** 2020-01
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2015-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02460068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02460068, "A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02460068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*